Citigroup’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.56M | Buy |
109,295
+40,640
| +59% | +$1.31M | ﹤0.01% | 2237 |
|
|
2025
Q4 | $2.42M | Sell |
68,655
-345,948
| -83% | -$12.3M | ﹤0.01% | 2535 |
|
|
2025
Q3 | $10.9M | Sell |
414,603
-449,508
| -52% | -$13.4M | ﹤0.01% | 1424 |
|
|
2025
Q2 | $22.9M | Buy |
864,111
+623,275
| +259% | +$16.4M | 0.01% | 899 |
|
|
2025
Q1 | $5.82M | Buy |
240,836
+62,189
| +35% | +$1.97M | ﹤0.01% | 1769 |
|
|
2024
Q4 | $7.19M | Buy |
178,647
+49,302
| +38% | +$2.81M | ﹤0.01% | 1639 |
|
|
2024
Q3 | $8.19M | Buy |
129,345
+30,957
| +31% | +$1.82M | ﹤0.01% | 1455 |
|
|
2024
Q2 | $5.22M | Sell |
98,388
-115,683
| -54% | -$7.58M | ﹤0.01% | 1597 |
|
|
2024
Q1 | $17.6M | Buy |
214,071
+35,248
| +20% | +$1.57M | 0.01% | 945 |
|
|
2023
Q4 | $3.33M | Sell |
178,823
-180,762
| -50% | -$2.36M | ﹤0.01% | 1865 |
|
|
2023
Q3 | $3.98M | Buy |
359,585
+191,826
| +114% | +$2.74M | ﹤0.01% | 1557 |
|
|
2023
Q2 | $2.72M | Sell |
167,759
-391,982
| -70% | -$8.21M | ﹤0.01% | 1933 |
|
|
2023
Q1 | $9.32M | Buy |
559,741
+431,531
| +337% | +$4.46M | 0.01% | 1193 |
|
|
2022
Q4 | $1.21M | Buy |
128,210
+122,781
| +2,262% | +$548K | ﹤0.01% | 2444 |
|
|
2022
Q3 | $15K | Buy |
5,429
+4,466
| +464% | +$14.6K | ﹤0.01% | 4860 |
|
|
2022
Q2 | $3K | Sell |
963
-4,226
| -81% | -$10.5K | ﹤0.01% | 5808 |
|
|
2022
Q1 | $16K | Sell |
5,189
-183,270
| -97% | -$657K | ﹤0.01% | 5285 |
|
|
2021
Q4 | $867K | Buy |
188,459
+94,365
| +100% | +$529K | ﹤0.01% | 3394 |
|
|
2021
Q3 | $591K | Sell |
94,094
-195,071
| -67% | -$1.21M | ﹤0.01% | 3499 |
|
|
2021
Q2 | $1.73M | Sell |
289,165
-143,347
| -33% | -$851K | ﹤0.01% | 2767 |
|
|
2021
Q1 | $2.73M | Buy |
432,512
+415,276
| +2,409% | +$2.92M | ﹤0.01% | 2270 |
|
|
2020
Q4 | $97K | Buy |
17,236
+4,711
| +38% | +$28.5K | ﹤0.01% | 5561 |
|
|
2020
Q3 | $73K | Sell |
12,525
-63,581
| -84% | -$438K | ﹤0.01% | 5341 |
|
|
2020
Q2 | $548K | Sell |
76,106
-6,722
| -8% | -$44.6K | ﹤0.01% | 4166 |
|
|
2020
Q1 | $388K | Sell |
82,828
-18,464
| -18% | -$114K | ﹤0.01% | 4112 |
|
|
2019
Q4 | $812K | Sell |
101,292
-202,060
| -67% | -$1.47M | ﹤0.01% | 3974 |
|
|
2019
Q3 | $2.09M | Sell |
303,352
-231,552
| -43% | -$1.72M | ﹤0.01% | 2824 |
|
|
2019
Q2 | $4.44M | Buy |
534,904
+478,867
| +855% | +$4.09M | ﹤0.01% | 2062 |
|
|
2019
Q1 | $557K | Sell |
56,037
-883,613
| -94% | -$7.4M | ﹤0.01% | 4073 |
|
|
2018
Q4 | $7.19M | Buy |
939,650
+612,741
| +187% | +$7.33M | 0.01% | 1518 |
|
|
2018
Q3 | $5.69M | Buy |
326,909
+317,866
| +3,515% | +$3.78M | 0.01% | 1737 |
|
|
2018
Q2 | $85K | Buy |
+9,043
| New | +$60.1K | ﹤0.01% | 5864 |
|
|
2016
Q2 | – | Sell |
-100
| Closed | – | – | 7468 |
|
|
2016
Q1 | $0 | Buy |
+100
| New | +$201 | ﹤0.01% | 7790 |
|
Other funds holding VKTX
VCM
VPM
Citigroup's VKTX Position: Q1 2026 in Review
Citigroup increased its Viking Therapeutics (VKTX) stake by 59% in Q1 2026, buying an estimated $1.31M and bringing the position to 109,295 shares worth $3.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2237.
Citigroup first reported a position in VKTX in Q1 2016 and has held it in 33 quarters since. The position peaked at $22.9M in Q2 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- Citigroup held 109,295 shares of Viking Therapeutics worth $3.56M as of Q1 2026.
- Citigroup bought 40,640 Viking Therapeutics shares in Q1 2026, an estimated $1.31M.
- Viking Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2237 holding.
- Citigroup first reported a position in Viking Therapeutics in Q1 2016 and has held it in 33 quarters since.
- Citigroup's Viking Therapeutics position peaked at $22.9M in Q2 2025.
- 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.